Depressive Disorder, Major

• 

  Subject Areas on Research

  • A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. 
  • A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. 
  • A Step Toward Optimizing Treatment Schedules for Continuation ECT: Response to Rasmussen. 
  • A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. 
  • A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom? 
  • A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. 
  • A comparison of pure and comorbid CD/ODD and depression. 
  • A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. 
  • A conceptual introduction to cognitive remediation for memory deficits associated with right unilateral electroconvulsive therapy. 
  • A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). 
  • A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. 
  • A family study of chronic post-traumatic stress disorder following rape trauma. 
  • A fidelity measure for integrated management of depression in primary care. 
  • A longitudinal examination of the psychoeducational, neurocognitive, and psychiatric functioning in children with 22q11.2 deletion syndrome. 
  • A longitudinal study of differences in late- and early-onset geriatric depression: depressive symptoms and psychosocial, cognitive, and neurological functioning. 
  • A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS). 
  • A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety. 
  • A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. 
  • A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. 
  • A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. 
  • A review of current evidence for vilazodone in major depressive disorder. 
  • A systematic overview of measurement-based care in the treatment of childhood and adolescent depression. 
  • A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. 
  • A systematic review of treatments for refractory depression in older people. 
  • AGTR1 gene variation: association with depression and frontotemporal morphology. 
  • APOE genotype and hippocampal volume change in geriatric depression. 
  • Acetyl-l-carnitine deficiency in patients with major depressive disorder. 
  • Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy. 
  • Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. 
  • Acute time to response in the Treatment for Adolescents with Depression Study (TADS). 
  • Adequacy of antidepressant treatment by psychiatric residents: the antidepressant treatment history form as a possible assessment tool. 
  • Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis. 
  • Adjunctive brexpiprazole for the treatment of major depressive disorder. 
  • Adjunctive use of olanzapine in mood disorders: five case reports. 
  • Adolescents with depression. 
  • Affective context interferes with cognitive control in unipolar depression: an fMRI investigation. 
  • Age differences in symptom expression in patients with major depression. 
  • Age-related characteristics of depression: a preliminary STAR*D report. 
  • Aggression after traumatic brain injury: prevalence and correlates. 
  • Allelic differences in the brain-derived neurotrophic factor Val66Met polymorphism in late-life depression. 
  • Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder. 
  • Amygdala volume in late-life depression: relationship with age of onset. 
  • Amyloid-associated depression: a prodromal depression of Alzheimer disease? 
  • An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. 
  • An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. 
  • An ecological-transactional model of significant risk factors for child psychopathology in outer mongolia. 
  • An exploration of comorbid depression among female victims of intimate partner violence with posttraumatic stress disorder. 
  • An exploratory analysis of the impact of family functioning on treatment for depression in adolescents. 
  • An interactive web-based method of outreach to college students at risk for suicide. 
  • An open label trial of C-1073 (mifepristone) for psychotic major depression. 
  • An open trial of morning light therapy for treatment of antepartum depression. 
  • An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. 
  • An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. 
  • Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders. 
  • Antidepressant response to electroconvulsive therapy is sustained after catecholamine depletion. 
  • Antidepressant treatment practice in the face of STAR*D and STEP-BD. 
  • Antipsychotic drugs for depression? 
  • Anxiety reduces baroreflex cardiac control in older adults with major depression. 
  • Anxiety, independent of depressive symptoms, is associated with in-hospital cardiac complications after acute myocardial infarction. 
  • Appetite and Weight Loss Symptoms in Late-Life Depression Predict Dementia Outcomes. 
  • Appetite loss and neurocognitive deficits in late-life depression. 
  • Applications of TMS to therapy in psychiatry. 
  • Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study. 
  • Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. 
  • Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. 
  • Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. 
  • Ascending digits task as a measure of executive function in geriatric depression. 
  • Assessing patient beliefs in a clinical trial of Hypericum perforatum in major depression. 
  • Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report. 
  • Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. 
  • Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients. 
  • Association between depression severity and neurocognitive function in major depressive disorder: a review and synthesis. 
  • Association between major depressive disorder and C-reactive protein levels in stable coronary heart disease patients. 
  • Association of AGTR1 with 18-month treatment outcome in late-life depression. 
  • Association of DHEA, DHEAS, and cortisol with childhood trauma exposure and post-traumatic stress disorder. 
  • Association of attentional shift and reversal learning to functional deficits in geriatric depression. 
  • Association of five-factor model personality domains and facets with presence, onset, and treatment outcomes of major depression in older adults. 
  • Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. 
  • Association of somatic symptoms with depression and anxiety in clinical patients of general hospitals in Guangzhou, China. 
  • Associations between sleep difficulties and risk factors for cardiovascular disease in veterans and active duty military personnel of the Iraq and Afghanistan conflicts. 
  • Attenuation of Frontostriatal Connectivity During Reward Processing Predicts Response to Psychotherapy in Major Depressive Disorder. 
  • Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. 
  • Atypical depression: a comprehensive review. 
  • Augmentation of dopaminergic agents for major depressive disorder. 
  • BDNF Val66Met genotype and 6-month remission rates in late-life depression. 
  • Baroreceptor sensitivity at rest and during stress in women with posttraumatic stress disorder or major depressive disorder. 
  • Basolateral amygdala volume and cell numbers in major depressive disorder: a postmortem stereological study. 
  • Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. 
  • Beliefs about sleep in disorders characterized by sleep and mood disturbance. 
  • Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. 
  • Better, Faster, Safer: Exploring Biomarkers of Response to Transform Electroconvulsive Therapy. 
  • Bifrontal, bitemporal and right unilateral electrode placement in ECT: randomised trial. 
  • Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression. 
  • Biological and social predictors of long-term geriatric depression outcome. 
  • Bipolar disorder is associated with HIV transmission risk behavior among patients in treatment for HIV. 
  • Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. 
  • Brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy (ECT) for major depression: efficacy, effectiveness, and cognitive effects. 
  • Cardiovascular disease risk, vascular health and erectile dysfunction among middle-aged, clinically depressed men. 
  • Case records of the Massachusetts General Hospital. Case 14-2008. A 78-year-old man with anergia and anhedonia associated with cardiovascular surgery. 
  • Case report of treatment of severe mood disorder in an inpatient setting: when less is more. 
  • Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. 
  • Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. 
  • Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. 
  • Cerebrovascular risk factors and cerebral hyperintensities among middle-aged and older adults with major depression. 
  • Cerebrovascular risk factors, vascular disease, and neuropsychological outcomes in adults with major depression. 
  • Challenging assumptions from emotion dysregulation psychological treatments. 
  • Child abuse and adult major depression: no evidence of protective gene. 
  • Childhood traumatic stress and obesity in women: the intervening effects of PTSD and MDD. 
  • Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice. 
  • Church attendance and new episodes of major depression in a community study of older adults: the Cache County Study. 
  • Cingulum bundle white matter lesions influence antidepressant response in late-life depression: a pilot study. 
  • Citalopram and the Curate's egg in geriatric depression. 
  • Clinical issues in use of atypical antipsychotics for depressed patients. 
  • Clomipramine and glucocorticoid receptor function. 
  • Coexistence of urinary incontinence and major depressive disorder with health-related quality of life in older Americans with and without cancer. 
  • Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial. 
  • Cognitive ability in early adulthood and risk of 5 specific psychiatric disorders in middle age: the Vietnam experience study. 
  • Cognitive aspects of chronic depression. 
  • Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. 
  • Cognitive effects of transcranial direct current stimulation treatment in patients with major depressive disorder: An individual patient data meta-analysis of randomised, sham-controlled trials. 
  • Cognitive enhancing effects of rTMS administered to the prefrontal cortex in patients with depression: A systematic review and meta-analysis of individual task effects. 
  • Cognitive functioning throughout the treatment history of clinical late-life depression. 
  • Cognitive measures of adolescent depression: unique or unitary constructs? 
  • Cognitive performance in antidepressant-free recurrent major depressive disorder. 
  • Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. 
  • Combined Treatment for Obesity and Depression: A Pilot Study. 
  • Combined catecholamine and indoleamine depletion following response to ECT. 
  • Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. 
  • Comorbid substance and mental disorders among rural Americans: results from the National Comorbidity Survey. 
  • Comorbidity and depression treatment. 
  • Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. 
  • Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. 
  • Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis. 
  • Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study. 
  • Comparison of academic and nonacademic sites in multi-center clinical trials. 
  • Comparison of brain structural variables, neuropsychological factors, and treatment outcome in early-onset versus late-onset late-life depression. 
  • Comparison of major and minor depression in older medical inpatients with chronic heart and pulmonary disease. 
  • Comparison of older depressed hospitalized patients with and without heart failure/pulmonary disease. 
  • Comparison of post-disaster psychiatric disorders after terrorist bombings in Nairobi and Oklahoma City. 
  • Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. 
  • Computerized adaptive test-depression inventory not ready for prime time. 
  • Computerized cognitive training and functional recovery in major depressive disorder: A meta-analysis. 
  • Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial". 
  • Concordance of self-rated and observer-rated dysphoric symptoms in mania. 
  • Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. 
  • Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). 
  • Cost-effectiveness of improving primary care treatment of late-life depression. 
  • Cost-effectiveness of treatments for adolescent depression: results from TADS. 
  • Cross-cultural considerations in administering the center for epidemiologic studies depression scale. 
  • Curcumin as a putative antidepressant. 
  • DAOA variants on diagnosis and response to treatment in patients with major depressive disorder and bipolar disorder. 
  • DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA's antidepressant action. 
  • Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. 
  • Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. 
  • Decreased Resting-State Activity in the Precuneus Is Associated With Depressive Episodes in Recurrent Depression. 
  • Default mode network connectivity in children with a history of preschool onset depression. 
  • Defining treatment-resistant depression: a comprehensive review of the literature. 
  • Depressed adolescents and comorbid psychiatric disorders: are there differences in the presentation of depression? 
  • Depressed older patients with the atypical features of interpersonal rejection sensitivity and reversed-vegetative symptoms are similar to younger atypical patients. 
  • Depression Among Older Adults: A 20-Year Update on Five Common Myths and Misconceptions. 
  • Depression after successful treatment for nonsmall cell lung carcinoma. 
  • Depression among military spouses: Demographic, military, and service member psychological health risk factors. 
  • Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. 
  • Depression and five year survival following acute myocardial infarction: a prospective study. 
  • Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. 
  • Depression in Taiwanese patients with Alzheimer's disease determined by the National Institutes of Mental Health Provisional Criteria. 
  • Depression in chronic illness: does religion help? 
  • Depression in patients with colorectal cancer in Saudi Arabia. 
  • Depression outcome in inpatients with congestive heart failure. 
  • Depression, homocysteine concentration, and cardiovascular events. 
  • Depression, suicidality, and alcohol use disorder among people living with HIV/AIDS in Nigeria. 
  • Depressive morbidity and gender in community-dwelling Brazilian elderly: systematic review and meta-analysis. 
  • Depressive state- and disease-related alterations in neural responses to affective and executive challenges in geriatric depression. 
  • Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. 
  • Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. 
  • Detection of depression in low resource settings: validation of the Patient Health Questionnaire (PHQ-9) and cultural concepts of distress in Nepal. 
  • Development of a semi-automated method for quantification of MRI gray and white matter lesions in geriatric subjects. 
  • Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. 
  • Diagnostic specificity and nonspecificity in the dimensions of preschool psychopathology. 
  • Diagnostic utility of the Quick Inventory of Depressive Symptomatology (QIDS-C16 and QIDS-SR16) in the elderly. 
  • Differences between depressed patients with heart failure and those with pulmonary disease. 
  • Differences between suicide attempters and nonattempters in depressed older patients: depression severity, white-matter lesions, and cognitive functioning. 
  • Differences in behavioral health disorders and unmet treatment needs between medical marijuana users and recreational marijuana users: Results from a national adult sample. 
  • Differences in early childhood risk factors for juvenile-onset and adult-onset depression. 
  • Dimensions of self-rated mood in depressed, manic, and normal subjects. 
  • Dimensions of social support and depression in patients at increased psychosocial risk recovering from myocardial infarction. 
  • Direct Participation in and Indirect Exposure to the Occupy Central Movement and Depressive Symptoms: A Longitudinal Study of Hong Kong Adults. 
  • Disability but not social support predicts cognitive deterioration in late-life depression. 
  • Discussing Out-of-Pocket Expenses During Clinical Appointments: An Observational Study of Patient-Psychiatrist Interactions. 
  • Disrupted amygdala reactivity in depressed 4- to 6-year-old children. 
  • Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. 
  • Does Childhood Trauma Moderate Polygenic Risk for Depression? A Meta-analysis of 5765 Subjects From the Psychiatric Genomics Consortium. 
  • Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? 
  • Does change in ECT electrode placement help temporomandibular joint pain? 
  • Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. 
  • Dynamic Resting-State Functional Connectivity in Major Depression. 
  • Dynamically Timed Stimulation of Corticolimbic Circuitry Activates a Stress-Compensatory Pathway. 
  • Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. 
  • Dysfunctional attitudes scale perfectionism: a predictor and partial mediator of acute treatment outcome among clinically depressed adolescents. 
  • Dysregulation of Prefrontal Cortex-Mediated Slow-Evolving Limbic Dynamics Drives Stress-Induced Emotional Pathology. 
  • ECT and TMS: past, present, and future. 
  • ECT in the presence of brain tumor and increased intracranial pressure: evaluation and reduction of risk. 
  • ECT use in unipolar and bipolar depression. 
  • EEG effects of ECT: implications for rTMS. 
  • EFFECTS OF RELIGIOUS VERSUS STANDARD COGNITIVE-BEHAVIORAL THERAPY ON OPTIMISM IN PERSONS WITH MAJOR DEPRESSION AND CHRONIC MEDICAL ILLNESS. 
  • Easing the burden of social anxiety disorder. 
  • Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. 
  • Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. 
  • Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. 
  • Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. 
  • Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study. 
  • Effects of Exercise and Sertraline on Measures of Coronary Heart Disease Risk in Patients With Major Depression: Results From the SMILE-II Randomized Clinical Trial. 
  • Effects of a Course of Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy Combined With Venlafaxine on Insomnia Symptoms in Elderly Depressed Patients. 
  • Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial. 
  • Effects of early life stress on depression, cognitive performance and brain morphology. 
  • Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. 
  • Effects of religious vs. standard cognitive behavioral therapy on therapeutic alliance: A randomized clinical trial. 
  • Effects on Daily Spiritual Experiences of Religious Versus Conventional Cognitive Behavioral Therapy for Depression. 
  • Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. 
  • Efficacy and safety of St. John's wort for the treatment of major depression. 
  • Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. 
  • Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials. 
  • Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial. 
  • Efficacy of a multimodal treatment for disruptive behavior disorders in children and adolescents: focus on internalizing problems. 
  • Efficacy of antidepressants: bias in randomized clinical trials and related issues. 
  • Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. 
  • Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. 
  • Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. 
  • Electric field characteristics of low-field synchronized transcranial magnetic stimulation (sTMS). 
  • Electroconvulsive Therapy and All-Cause Mortality in Texas, 1998-2013. 
  • Electroconvulsive therapy device classification: response to FDA advisory panel hearing and recommendations. 
  • Electroconvulsive therapy for depression. 
  • Electroconvulsive therapy for severe major depressive disorder after orthotopic liver transplantation. 
  • Electroconvulsive therapy in the United States: how often is it used? 
  • Electroconvulsive therapy is equally effective in unipolar and bipolar depression. 
  • Electroconvulsive therapy: how effective is it? 
  • Elevated brain lesion volumes in older adults who use calcium supplements: a cross-sectional clinical observational study. 
  • Elevated inflammation levels in depressed adults with a history of childhood maltreatment. 
  • Elevation in plasma Abeta42 in geriatric depression: a pilot study. 
  • Emotion Regulation in Borderline Personality Disorder: An Experimental Investigation of the Effects of Instructed Acceptance and Suppression. 
  • Emotional distress in nonmetropolitan persons living with HIV disease enrolled in a telephone-delivered, coping improvement group intervention. 
  • Empirically derived subtypes of adolescent depression: latent profile analysis of co-occurring symptoms in the Treatment for Adolescents with Depression Study (TADS). 
  • Escitalopram for the treatment of major depressive disorder in youth. 
  • Ethnic differences among adolescents beginning treatment for depression. 
  • Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. 
  • Evaluation of lifetime trauma exposure and physical health in women with posttraumatic stress disorder or major depressive disorder. 
  • Everyday discrimination and mood and substance use disorders: a latent profile analysis with African Americans and Caribbean Blacks. 
  • Evidence for impaired cortical inhibition in patients with unipolar major depression. 
  • Evidence of early retinal microvascular changes in patients with type 2 diabetes and depression. 
  • Examining the factor structure of the Connor-Davidson Resilience Scale (CD-RISC) in a post-9/11 U.S. military veteran sample. 
  • Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. 
  • Exercise and pharmacotherapy in the treatment of major depressive disorder. 
  • Exercise fails to improve neurocognition in depressed middle-aged and older adults. 
  • Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. 
  • Factor structure and psychometric properties of the Children's Negative Cognitive Error Questionnaire with a clinically depressed adolescent sample. 
  • Family history of depression and therapeutic outcome: findings from STAR*D. 
  • Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. 
  • Fiber tract-specific white matter lesion severity Findings in late-life depression and by AGTR1 A1166C genotype. 
  • Financial well-being and postdeployment adjustment among Iraq and Afghanistan war veterans. 
  • Five-year trajectories of social networks and social support in older adults with major depression. 
  • Flexible dosing schedules for continuation electroconvulsive therapy. 
  • Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. 
  • Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. 
  • Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study. 
  • Focal brain stimulation with repetitive transcranial magnetic stimulation (rTMS): implications for the neural circuitry of depression. 
  • Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment. 
  • Food group intake and brain lesions in late-life vascular depression. 
  • Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. 
  • Functional brain activation to emotionally valenced faces in school-aged children with a history of preschool-onset major depression. 
  • Functional connectivity of the amygdala in early-childhood-onset depression. 
  • Functional connectivity: a source of variance in the association between cardiorespiratory fitness and cognition? 
  • Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. 
  • Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). 
  • Gender differences in the association between religious involvement and depression: the Cache County (Utah) study. 
  • General medical and specialty mental health service use for major depression. 
  • Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32. 
  • Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. 
  • Genetic association study of individual symptoms in depression. 
  • Genetic prediction of antidepressant drug response and nonresponse in Korean patients. 
  • Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. 
  • Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. 
  • Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. 
  • Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. 
  • Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. 
  • Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. 
  • Genome-wide interaction study of a proxy for stress-sensitivity and its prediction of major depressive disorder. 
  • Geriatric depression and cognitive impairment. 
  • Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. 
  • Greater MRI lesion volumes in elderly depressed subjects than in control subjects. 
  • Grey-matter lesions and dementia. 
  • Guideline-concordant antidepressant use among patients with major depressive disorder. 
  • Hardly depressing and far from painful: commentary on an article by Daniel A. London, BA, et al.: "the impact of depression and pain catastrophization on initial presentation and treatment outcomes for atraumatic hand conditions". 
  • Head injury in early adulthood and the lifetime risk of depression. 
  • Heat-shock protein-70 genes and response to antidepressants in major depression. 
  • Heterogeneity in symptom profiles among older adults diagnosed with major depression. 
  • Heterogeneity in the three-year course of major depression among older adults. 
  • Hippocampal structural and functional changes associated with electroconvulsive therapy response. 
  • Hippocampal volume as a predictor of short-term ECT outcomes in older patients with depression. 
  • Hippocampal volume in geriatric depression. 
  • Hippocampal volume is associated with physician-reported acute cognitive deficits after electroconvulsive therapy. 
  • Hippocampus atrophy and the longitudinal course of late-life depression. 
  • History of depression and survival after acute myocardial infarction. 
  • Hormone therapy does not affect depression severity in older women. 
  • Hyperactivity of the hypothalamic-pituitary-adrenal axis and mortality in major depressive disorder. 
  • Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. 
  • Identifying depression in primary care: a literature synthesis of case-finding instruments. 
  • Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS). 
  • Impact of comorbid panic and posttraumatic stress disorder on outcomes of collaborative care for late-life depression in primary care. 
  • Impact of depression and anxiety on the quality of life of constipated patients. 
  • Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study. 
  • Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. 
  • Impact of sleep complaints and depression outcomes among participants in the standard medical intervention and long-term exercise study of exercise and pharmacotherapy for depression. 
  • Impact of symptoms of generalized anxiety disorder on the course of late-life depression. 
  • Improvement in quality of life with left prefrontal transcranial magnetic stimulation in patients with pharmacoresistant major depression: acute and six month outcomes. 
  • Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial. 
  • Improving depression outcomes in older adults with comorbid medical illness. 
  • Increased prevalence of falls among elderly individuals with mental health and substance abuse conditions. 
  • Increasing the validity of experimental models for depression. 
  • Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. 
  • Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. 
  • Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. 
  • Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. 
  • Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. 
  • Insight in first-episode psychosis. 
  • Instrumental variable estimation of causal odds ratios using structural nested mean models. 
  • Interaction of oxytocin level and past depression may predict postpartum depressive symptom severity. 
  • Interactive effect of substance abuse and depression on adolescent social competence. 
  • International consensus statement on major depressive disorder. 
  • International randomized-controlled trial of transcranial Direct Current Stimulation in depression. 
  • Intima-media thickness and age of first depressive episode. 
  • Intravenous Ketamine Relieves Pain and Depression After Traumatic Suicide Attempts: A Case Series. 
  • Investigation of an epistastic effect between a set of TAAR6 and HSP-70 genes variations and major mood disorders. 
  • Investigation of possible epistatic interactions between GRIA2 and GRIA4 variants on clinical outcomes in patients with major depressive disorder. 
  • Is Major Depression Linked to Alcohol-Impaired Driving? 
  • Is depression associated with immune activation? 
  • Is depression associated with microvascular disease in patients with type 2 diabetes? 
  • Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. 
  • Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. 
  • Key updates in the clinical application of electroconvulsive therapy. 
  • Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. 
  • Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability. 
  • Late-life Depression Modifies the Association Between Cerebral White Matter Hyperintensities and Functional Decline Among Older Adults. 
  • Late-life depression and microstructural abnormalities in dorsolateral prefrontal cortex white matter. 
  • Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder. 
  • Length of axons expressing the serotonin transporter in orbitofrontal cortex is lower with age in depression. 
  • Lessons from SADHART, ENRICHD, and other trials. 
  • Life Span Studies of ADHD-Conceptual Challenges and Predictors of Persistence and Outcome. 
  • Lifetime major depression and comorbid disorders among current-era women veterans. 
  • Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. 
  • Localization of age-associated white matter hyperintensities in late-life depression. 
  • Longitudinal magnetic resonance imaging vascular changes, apolipoprotein E genotype, and development of dementia in the neurocognitive outcomes of depression in the elderly study. 
  • Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. 
  • Low yield of thyroid-stimulating hormone testing in elderly patients with depression. 
  • Magnetic seizure therapy improves mood in refractory major depression. 
  • Major depression and physical illness trajectories in heart failure and pulmonary disease. 
  • Major depression, antidepressant use, and male and female fertility. 
  • Major depression, generalized anxiety disorder, and panic disorder in patients scheduled for knee arthroplasty. 
  • Major depressive disorder is characterized by greater reward network activation to monetary than pleasant image rewards. 
  • Major depressive disorder treatment guidelines in America and Europe. 
  • Major depressive disorder with psychotic features may lead to misdiagnosis of dementia: a case report and review of the literature. 
  • Managing depression in countries with low and middle incomes: an imperative for human immunodeficiency virus/acquired immune deficiency syndrome care and treatment and general public health. 
  • Managing depression in geriatric populations. 
  • Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. 
  • Medial orbital frontal lesions in late-onset depression. 
  • Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. 
  • Medication-Assisted Treatment for Alcohol-Dependent Adults With Serious Mental Illness and Criminal Justice Involvement: Effects on Treatment Utilization and Outcomes. 
  • Mental health service use among adolescents following participation in a randomized clinical trial for depression. 
  • Meta-analysis of Genome-wide Association Studies for Neuroticism, and the Polygenic Association With Major Depressive Disorder. 
  • Metabolomic differences in heart failure patients with and without major depression. 
  • Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. 
  • Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. 
  • Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. 
  • Methodology and preliminary results from the neurocognitive outcomes of depression in the elderly study. 
  • Mifepristone in psychotic depression? 
  • Milnacipran: beyond a role of antidepressant. 
  • Minor depression in family practice: functional morbidity, co-morbidity, service utilization and outcomes. 
  • Mixed depression: a study of its phenomenology and relation to treatment response. 
  • Modification of Hostile Interpretation Bias in Depression: A Randomized Controlled Trial. 
  • Modification of depression by COMT val158met polymorphism in children exposed to early severe psychosocial deprivation. 
  • Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. 
  • More data on speed of remission with ECT in geriatric depression. 
  • Morphometric analysis of vascular pathology in the orbitofrontal cortex of older subjects with major depression. 
  • Negative Affectivity, Aging, and Depression: Results From the Neurobiology of Late-Life Depression (NBOLD) Study. 
  • Neighborhood structural characteristics and mental disorder: Faris and Dunham revisited. 
  • Neural indicators of emotion regulation via acceptance vs reappraisal in remitted major depressive disorder. 
  • Neural mechanisms of cognitive reappraisal in remitted major depressive disorder. 
  • Neurocognitive correlates of response to treatment in late-life depression. 
  • Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. 
  • Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. 
  • Neuropsychological predictors of dementia in late-life major depressive disorder. 
  • Neurosteroid Levels in Patients With Bipolar Disorder and a History of Cannabis Use Disorders. 
  • Neuroticism Traits Selectively Impact Long Term Illness Course and Cognitive Decline in Late-Life Depression. 
  • New developments in electroconvulsive therapy and magnetic seizure therapy. 
  • Novel melatonin-based treatments for major depression. 
  • On the Concurrent Use of Self-System Therapy and Functional Magnetic Resonance Imaging-Guided Transcranial Magnetic Stimulation as Treatment for Depression. 
  • Onset of alcohol or substance use disorders following treatment for adolescent depression. 
  • Orbitofrontal cortex volume in late life depression: influence of hyperintense lesions and genetic polymorphisms. 
  • PC-FACS. 
  • Palliative care pharmacotherapy literature summaries and analyses. 
  • Partial remission. A common outcome in older adults treated for major depression. 
  • Partial response as a predictor of outcome in geriatric depression. 
  • Pastoral care use among post-9/11 veterans who screen positive for mental health problems. 
  • Pathophysiology of hypercortisolism in depression. 
  • Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback. 
  • Patterns and correlates of major depression in Chinese adults: a cross-sectional study of 0.5 million men and women. 
  • Performance feedback deficit in geriatric depression. 
  • Persistent mild cognitive impairment in geriatric depression. 
  • Personality--life event congruence effects in late-life depression. 
  • Perspectives on depression, mild cognitive impairment, and cognitive decline. 
  • Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. 
  • Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. 
  • Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. 
  • Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. 
  • Physical and sexual abuse, depression and alcohol use disorders in adolescents: onsets and outcomes. 
  • Physical frailty in late-life depression is associated with deficits in speed-dependent executive functions. 
  • Physician attitudes toward treatment of depression in older medical inpatients. 
  • Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. 
  • Polygenic loading for major depression is associated with specific medical comorbidity. 
  • Posttraumatic stress disorder and traumatic brain Injury: Sex differences in veterans. 
  • Practitioner review: the assessment of bipolar disorder in children and adolescents. 
  • Pre-existing major depression predicts in-hospital cardiac complications after acute myocardial infarction. 
  • Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation: Results from an international randomized controlled trial. 
  • Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependence. 
  • Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). 
  • Predictors of depression outcomes in medical inpatients with chronic pulmonary disease. 
  • Predictors of depression recovery in HIV-infected individuals managed through measurement-based care in infectious disease clinics. 
  • Predictors of hopelessness among clinically depressed youth. 
  • Predictors of partial remission in older patients treated for major depression: the role of comorbid dysthymia. 
  • Predictors of recurrence in remitted late-life depression. 
  • Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS). 
  • Predisposition locus for major depression at chromosome 12q22-12q23.2. 
  • Prefrontal cortex, thalamus, and cerebellar volumes in adolescents and young adults with adolescent-onset alcohol use disorders and comorbid mental disorders. 
  • Prefrontal mechanisms for executive control over emotional distraction are altered in major depression. 
  • Prenatal dysthymia versus major depression effects on maternal cortisol and fetal growth. 
  • Prescription pain reliever abuse and dependence among adolescents: a nationally representative study. 
  • Pretreatment brain connectivity during positive emotion upregulation predicts decreased anhedonia following behavioral activation therapy for depression. 
  • Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. 
  • Prevalence and costs of major depression among elderly claimants with diabetes. 
  • Prevalence and incidence of probable perinatal depression among women enrolled in Option B+ antenatal HIV care in Malawi. 
  • Prevalence, course, and predictors of emotional distress in pregnant and parenting adolescents. 
  • Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. 
  • Problem alcohol use and healthcare utilization among persons with cannabis use disorder in the United States. 
  • Profiles of depressive symptoms in older adults diagnosed with major depression: latent cluster analysis. 
  • Psychiatric comorbidity in depressed HIV-infected individuals: common and clinically consequential. 
  • Psychiatric sequelae of traumatic brain injury: a case report. 
  • Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. 
  • Psychosocial Predictors of Mortality Following Lung Transplantation. 
  • Psychosocial and clinical predictors of unipolar depression outcome in older adults. 
  • Psychosocial and physical correlates of chronic depression. 
  • Puberty and depression. 
  • Putamen Volume Differences Among Older Adults: Depression Status, Melancholia, and Age. 
  • Quality of life and physical activity associated to lower prevalence of depression in community-dwelling elderly subjects from Sao Paulo. 
  • Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. 
  • Quantifying heterogeneity attributable to polythetic diagnostic criteria: theoretical framework and empirical application. 
  • Quetiapine XR: current status for the treatment of major depressive disorder. 
  • Quetiapine augmentation for depression: dosing pattern in routine practice. 
  • Quick recovery of orientation after magnetic seizure therapy for major depressive disorder. 
  • Quinone oxidoreductase (NQO1) gene polymorphism may not confer a susceptibility to mood disorders. 
  • RCT of a psychological intervention for patients with cancer: I. mechanisms of change. 
  • Race/ethnicity differences between alcohol, marijuana, and co-occurring alcohol and marijuana use disorders and their association with public health and social problems using a national sample. 
  • Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. 
  • Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression. 
  • Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. 
  • Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. 
  • Rapid screening for major depression in post-myocardial infarction patients: an investigation using Beck Depression Inventory II items. 
  • Recognition of depression in medical patients with heart failure. 
  • Recovery and recurrence following treatment for adolescent major depression. 
  • Reducing barriers to completing psychiatric advance directives. 
  • Reductions in neuronal density in elderly depressed are region specific. 
  • Relapse of depression after electroconvulsive therapy. 
  • Relationship Between Chronic Conditions and Disability in African American Men and Women. 
  • Relationship between traumatic brain injury history and recent suicidal ideation in Iraq/Afghanistan-era veterans. 
  • Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. 
  • Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. 
  • Relative effectiveness of reappraisal and distraction in regulating emotion in late-life depression. 
  • Reliability and Validity of the Vietnamese Depression Interview (VDI). 
  • Religion and depression in older medical inpatients. 
  • Religion and remission of depression in medical inpatients with heart failure/pulmonary disease. 
  • Religion and the presence and severity of depression in older adults. 
  • Religion, spirituality, and depression in adolescent psychiatric outpatients. 
  • Religion, spirituality, and mental health of U.S. military veterans: Results from the National Health and Resilience in Veterans Study. 
  • Religion/spirituality and depression: what can we learn from empirical studies? 
  • Religious service attendance and major depression: a case of reverse causality? 
  • Religious vs. conventional cognitive behavioral therapy for major depression in persons with chronic medical illness: a pilot randomized trial. 
  • Religiously integrated cognitive behavioral therapy: a new method of treatment for major depression in patients with chronic medical illness. 
  • Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes. 
  • Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). 
  • Remitted major depression is characterized by reduced prefrontal cortex reactivity to reward loss. 
  • Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomes. 
  • Repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of panic disorder (PD) with comorbid major depression. 
  • Repetitive Transcranial Magnetic Stimulation of the Supplementary Motor Area in the treatment of Tourette Syndrome: report of two cases. 
  • Reply to: Declining use of electroconvulsive therapy in U.S. general hospitals is not restricted to unipolar depression. 
  • Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS). 
  • Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. 
  • Residual symptoms in older patients treated for major depression. 
  • Resolution of trauma-related guilt following treatment of PTSD in female rape victims: a result of cognitive processing therapy targeting comorbid depression? 
  • Resolved: psychosocial interventions can improve clinical outcomes in organic disease (pro). 
  • Response inhibition predicts poor antidepressant treatment response in very old depressed patients. 
  • Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45, 11-16. 
  • Resting-state connectivity predictors of response to psychotherapy in major depressive disorder. 
  • Resting-state mapping of neural signatures of vulnerability to depression relapse. 
  • Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. 
  • Risk Factors for New-Onset Depression After First-Time Traumatic Brain Injury. 
  • Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. 
  • Screening for Depression in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement. 
  • Screening for Major Depressive Disorder in Children and Adolescents: A Systematic Review for the U.S. Preventive Services Task Force. 
  • Screening for depression in cancer patients receiving radiotherapy: Feasibility and identification of effective tools in the NRG Oncology RTOG 0841 trial. 
  • Screening for major depression in post-myocardial infarction patients: operating characteristics of the Beck Depression Inventory-II. 
  • Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. 
  • Seize the Day to Implement Depression Guidelines. 
  • Seizure induction with low-amplitude-current (0.5 A) electroconvulsive therapy. 
  • Selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable? 
  • Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. 
  • Self-punishment as a regulation strategy in borderline personality disorder. 
  • Self-regulation, rumination, and vulnerability to depression in adolescent girls. 
  • Self-reported health and physician diagnosed illnesses in women with posttraumatic stress disorder and major depressive disorder. 
  • Self-reported pain complaints among Afghanistan/Iraq era men and women veterans with comorbid posttraumatic stress disorder and major depressive disorder. 
  • Sensitivity of cognitive tests in four cognitive domains in discriminating MDD patients from healthy controls: a meta-analysis. 
  • Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. 
  • Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results. 
  • Serotonin transporter genotype and function in relation to antidepressant response in Koreans. 
  • Sertraline and the Cheshire cat in geriatric depression. 
  • Sertraline and the Cheshire cat in geriatric depression. 
  • Sertraline treatment of major depression in patients with acute MI or unstable angina. 
  • Service use and costs of care for depressed adolescents: who uses and who pays? 
  • Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. 
  • Shifting priorities: highly conserved behavioral and brain network adaptations to chronic stress across species. 
  • Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. 
  • Short/long heterozygotes at 5HTTLPR and white matter lesions in geriatric depression. 
  • Sleep disturbance in psychiatric disorders: effects on function and quality of life in mood disorders, alcoholism, and schizophrenia. 
  • Smoking cessation and the course of major depression: a follow-up study. 
  • Smoking-induced affect modulation in nonwithdrawn smokers with posttraumatic stress disorder, depression, and in those with no psychiatric disorder. 
  • Social support and locus of control as predictors of adherence to antidepressant medication in an elderly population. 
  • Social support modifies the relationship between personality and depressive symptoms in older adults. 
  • Somatic, positive and negative domains of the Center for Epidemiological Studies Depression (CES-D) scale: a meta-analysis of genome-wide association studies. 
  • Specific psychotherapies for childhood and adolescent depression. 
  • Speed of response to electroconvulsive therapy compared with ketamine. 
  • Spirituality and distress in sheltered battered women. 
  • St John's wort and depression. 
  • State of the Science of Neural Systems in Late-Life Depression: Impact on Clinical Presentation and Treatment Outcome. 
  • Stressful life events, perceived stress, and 12-month course of geriatric depression: direct effects and moderation by the 5-HTTLPR and COMT Val158Met polymorphisms. 
  • Structural brain changes as biomarkers and outcome predictors in patients with late-life depression: a cross-sectional and prospective study. 
  • Structural-functional correlations between hippocampal volume and cortico-limbic emotional responses in depressed children. 
  • Study design and methodology for a multicentre, randomised controlled trial of transcranial direct current stimulation as a treatment for unipolar and bipolar depression. 
  • Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression. 
  • Subcortical white matter lesions and functional impairment in geriatric depression. 
  • Suicidal events in the Treatment for Adolescents With Depression Study (TADS). 
  • Suicide Behaviors in Bipolar Disorder: A Review and Update for the Clinician. 
  • Suicide risk and efficacy of antidepressant drugs--reply. 
  • Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. 
  • Sustained anterior cingulate cortex activation during reward processing predicts response to psychotherapy in major depressive disorder. 
  • Systematic review of multifaceted interventions to improve depression care. 
  • T-lymphocyte CREB as a potential biomarker of response to antidepressant drugs. 
  • TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. 
  • Test of mindfulness and hope components in a psychological intervention for women with cancer recurrence. 
  • Testing a social-cognitive model of HIV transmission risk behaviors in HIV-infected MSM with and without depression. 
  • Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). 
  • Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. 
  • The 2-week duration criterion and severity and course of early childhood depression: implications for nosology. 
  • The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. 
  • The National Lesbian Family Study: 3. Interviews with mothers of five-year-olds. 
  • The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics. 
  • The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. 
  • The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. 
  • The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. 
  • The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. 
  • The Use of Antidepressants in Bipolar Depression. 
  • The association between cognitive function and subsequent depression: a systematic review and meta-analysis. 
  • The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: results from a national sample. 
  • The caregiving environments provided to children by depressed mothers with or without an antisocial history. 
  • The critical warzone experiences (CWE) scale: initial psychometric properties and association with PTSD, anxiety, and depression. 
  • The depression treatment cascade in primary care: a public health perspective. 
  • The dysfunctional attitudes scale: psychometric properties in depressed adolescents. 
  • The effects of Brief Behavioral Activation Therapy for Depression on cognitive control in affective contexts: An fMRI investigation. 
  • The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. 
  • The effects of psychotherapy on neural responses to rewards in major depression. 
  • The efficacy of acute electroconvulsive therapy in atypical depression. 
  • The emerging role for repetitive transcranial magnetic stimulation in optimizing the treatment of adolescent depression. 
  • The epidemiology of major depression and ethnicity in the United States. 
  • The epidemiology of trauma and post-traumatic stress disorder in a representative cohort of young people in England and Wales. 
  • The high prevalence of multiple psychiatric disorders in stable outpatients with coronary heart disease. 
  • The impact of race on metabolic disease risk factors in women with and without posttraumatic stress disorder. 
  • The impairment of Presidents Pierce and Coolidge after traumatic bereavement. 
  • The influence of anxiety and depression on outcomes of patients with coronary artery disease. 
  • The influence of depressive symptoms on suicidal ideation among U.S. Vietnam-era and Afghanistan/Iraq-era veterans with posttraumatic stress disorder. 
  • The influence of lifetime depression on self-reported memory and cognitive problems: results from the National Comorbidity Survey-Replication. 
  • The influence of maternal stress and distress on disruptive behavior problems in boys. 
  • The intricate link between violence and mental disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. 
  • The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS Trial. 
  • The psychometric properties of the MASC in a pediatric psychiatric sample. 
  • The relationship between fibromyalgia and major depressive disorder: a comprehensive review. 
  • The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. 
  • The relationship of person-specific eveningness chronotype, greater seasonality, and less rhythmicity to suicidal behavior: A literature review. 
  • The role of readiness to change in response to treatment of adolescent depression. 
  • The vascular depression subtype: evidence of internal validity. 
  • Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder. 
  • Three-year incidence of first-onset depressive syndrome in a population sample of older adults: the Cache County study. 
  • Thyroid hormones affect recovery from depression during antidepressant treatment. 
  • Trait anger, anger expression, and suicide attempts among adolescents and young adults: a prospective study. 
  • Trajectories of Functioning Into Emerging Adulthood Following Treatment for Adolescent Depression. 
  • Trajectories of mobility and IADL function in older patients diagnosed with major depression. 
  • Trajectories of preschool disorders to full DSM depression at school age and early adolescence: continuity of preschool depression. 
  • Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. 
  • Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. 
  • Transdermal selegiline: the new generation of monoamine oxidase inhibitors. 
  • Trauma-focused cognitive-behavioral therapy for posttraumatic stress disorder in three-through six year-old children: a randomized clinical trial. 
  • Treating insomnia in depression: Insomnia related factors predict long-term depression trajectories. 
  • Treatment course with antidepressant therapy in late-life depression. 
  • Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. 
  • Treatment for Adolescents with Depression Study (TADS): safety results. 
  • Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. 
  • Treatment of older adults with co-morbid personality disorder and depression: a dialectical behavior therapy approach. 
  • Treatment of posttraumatic stress disorder reduces suicidal ideation. 
  • Treatment of recurrent mental depression with imipramine. 
  • Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study. 
  • Treatments for alcohol dependence: rethinking the role of comorbidity and clinical subtypes. 
  • Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015. 
  • Two Studies of Connectedness to Parents and Suicidal Thoughts and Behavior in Children and Adolescents. 
  • Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. 
  • Unipolar depression does not moderate responses to the Sweet Taste Test. 
  • Update on magnetic seizure therapy: a novel form of convulsive therapy. 
  • Use of the SF-36v2 Health Survey as a Screen for Risk of Major Depressive Disorder in a US Population-based Sample and Subgroup With Chronic Pain. 
  • VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. 
  • Vagus nerve stimulation. A potential therapy for resistant depression? 
  • Vagus nerve stimulation: a new tool for brain research and therapy. 
  • Validation of a treatment algorithm for major depression in an older Brazilian sample. 
  • Validity of an interviewer-administered patient health questionnaire-9 to screen for depression in HIV-infected patients in Cameroon. 
  • Vascular depression prevalence and epidemiology in the United States. 
  • Vascular nutritional correlates of late-life depression. 
  • Ventral striatum reactivity to reward and recent life stress interact to predict positive affect. 
  • Vmat2 heterozygous mutant mice display a depressive-like phenotype. 
  • Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. 
  • Weight changes in postpartum women with remitted depression. 
  • White matter abnormalities in major depression: evidence from post-mortem, neuroimaging and genetic studies. 
  • White matter and subcortical gray matter lesion volume changes and late-life depression outcome: a 4-year magnetic resonance imaging study. 
  • White matter hyperintensity progression and late-life depression outcomes. 
  • White matter lesion volumes and caudate volumes in late-life depression. 
  • Why do trauma survivors become depressed? Testing the behavioral model of depression in a nationally representative sample. 
  • Work stress precipitates depression and anxiety in young, working women and men. 
  • fMRI of alterations in reward selection, anticipation, and feedback in major depressive disorder. 
  • iTRAQ-Based Proteomics Suggests Ephb6 as a Potential Regulator of the ERK Pathway in the Prefrontal Cortex of Chronic Social Defeat Stress Model Mice. 
  • miR-149 and miR-29c as candidates for bipolar disorder biomarkers. 
• 

  Keywords of People

  • McClintock, Shawn Michael, Adjunct Associate Professor in the Department of Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Brain Stimulation and Neurophysiology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Olsen, Maren Karine, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine